Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...
Idorsia is making moves to stretch its cash reserves further. The Swiss drugmaker said it is narrowing its ...
President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...
Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...
Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...
Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...
FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...
Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...
Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...
The Biden administration proposed a new rule Tuesday that would expand Medicare and Medicaid coverage of popular ...
The transition team for President-elect Donald Trump was still searching for its next National Institutes of Health director ...
Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback